| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypospadias | 8 | 2023 | 81 | 3.150 |
Why?
|
| Urinary Bladder, Neurogenic | 7 | 2023 | 45 | 2.980 |
Why?
|
| Circumcision, Male | 5 | 2022 | 25 | 2.200 |
Why?
|
| Lower Urinary Tract Symptoms | 5 | 2018 | 30 | 2.030 |
Why?
|
| Botulinum Toxins, Type A | 4 | 2023 | 167 | 1.980 |
Why?
|
| Urinary Incontinence | 6 | 2020 | 69 | 1.870 |
Why?
|
| Bone Morphogenetic Protein 7 | 5 | 2015 | 23 | 1.810 |
Why?
|
| Ureteral Obstruction | 9 | 2023 | 105 | 1.800 |
Why?
|
| Urology | 5 | 2024 | 74 | 1.540 |
Why?
|
| Nerve Block | 2 | 2022 | 68 | 1.410 |
Why?
|
| Penis | 6 | 2022 | 97 | 1.390 |
Why?
|
| Kidney Diseases | 5 | 2016 | 478 | 1.330 |
Why?
|
| Urinary Bladder | 7 | 2018 | 242 | 1.310 |
Why?
|
| Urethral Diseases | 2 | 2020 | 17 | 1.010 |
Why?
|
| Terminology as Topic | 3 | 2020 | 229 | 0.980 |
Why?
|
| Urinary Bladder, Overactive | 2 | 2023 | 28 | 0.950 |
Why?
|
| Meningomyelocele | 3 | 2023 | 222 | 0.900 |
Why?
|
| Postoperative Complications | 6 | 2023 | 3007 | 0.830 |
Why?
|
| Urination Disorders | 2 | 2014 | 17 | 0.810 |
Why?
|
| Pain, Postoperative | 3 | 2023 | 255 | 0.800 |
Why?
|
| Child | 40 | 2024 | 24208 | 0.790 |
Why?
|
| Muscle, Smooth | 3 | 2010 | 136 | 0.790 |
Why?
|
| Epididymitis | 1 | 2021 | 1 | 0.770 |
Why?
|
| Orchitis | 1 | 2021 | 2 | 0.770 |
Why?
|
| Urodynamics | 7 | 2024 | 39 | 0.770 |
Why?
|
| Disorders of Sex Development | 4 | 2020 | 78 | 0.770 |
Why?
|
| Vas Deferens | 1 | 2021 | 22 | 0.760 |
Why?
|
| Penile Diseases | 2 | 2020 | 11 | 0.760 |
Why?
|
| Muscarinic Antagonists | 2 | 2013 | 38 | 0.740 |
Why?
|
| Urinary Bladder Diseases | 1 | 2021 | 35 | 0.730 |
Why?
|
| Urinary Fistula | 1 | 2020 | 20 | 0.730 |
Why?
|
| Cutaneous Fistula | 1 | 2020 | 22 | 0.720 |
Why?
|
| Constipation | 2 | 2020 | 113 | 0.700 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2021 | 68 | 0.690 |
Why?
|
| Limb Deformities, Congenital | 1 | 2020 | 105 | 0.680 |
Why?
|
| Dwarfism | 1 | 2020 | 101 | 0.680 |
Why?
|
| Urination | 3 | 2021 | 21 | 0.670 |
Why?
|
| Urinary Tract Infections | 2 | 2023 | 293 | 0.670 |
Why?
|
| Male | 51 | 2024 | 60021 | 0.660 |
Why?
|
| Pain Measurement | 1 | 2021 | 352 | 0.650 |
Why?
|
| Adrenergic alpha-Antagonists | 3 | 2009 | 46 | 0.630 |
Why?
|
| Craniofacial Abnormalities | 1 | 2020 | 244 | 0.630 |
Why?
|
| Wolfram Syndrome | 1 | 2018 | 1 | 0.620 |
Why?
|
| Testis | 1 | 2020 | 405 | 0.620 |
Why?
|
| Adolescent | 27 | 2023 | 19086 | 0.610 |
Why?
|
| Humans | 74 | 2024 | 123199 | 0.610 |
Why?
|
| Urogenital Abnormalities | 1 | 2020 | 168 | 0.610 |
Why?
|
| Pons | 1 | 2018 | 32 | 0.610 |
Why?
|
| Ureter | 5 | 2023 | 96 | 0.600 |
Why?
|
| Enterostomy | 1 | 2017 | 5 | 0.580 |
Why?
|
| Parents | 2 | 2021 | 1023 | 0.550 |
Why?
|
| Analgesics, Opioid | 1 | 2021 | 401 | 0.540 |
Why?
|
| Child, Preschool | 23 | 2023 | 13862 | 0.530 |
Why?
|
| Urinary Tract | 2 | 2014 | 60 | 0.520 |
Why?
|
| Kidney | 5 | 2020 | 1338 | 0.500 |
Why?
|
| Kidney Tubules, Distal | 1 | 2015 | 17 | 0.500 |
Why?
|
| Urinary Bladder Neck Obstruction | 2 | 2009 | 28 | 0.500 |
Why?
|
| Incidence | 9 | 2022 | 3050 | 0.490 |
Why?
|
| Vesico-Ureteral Reflux | 4 | 2023 | 79 | 0.470 |
Why?
|
| Kidney Tubules, Proximal | 1 | 2015 | 109 | 0.460 |
Why?
|
| Urinary Tract Physiological Phenomena | 1 | 2014 | 2 | 0.460 |
Why?
|
| Treatment Outcome | 15 | 2023 | 12103 | 0.450 |
Why?
|
| Mandelic Acids | 1 | 2013 | 6 | 0.450 |
Why?
|
| Prospective Studies | 8 | 2022 | 6028 | 0.440 |
Why?
|
| Spinal Dysraphism | 2 | 2017 | 262 | 0.440 |
Why?
|
| Infant | 16 | 2023 | 12323 | 0.440 |
Why?
|
| Transforming Growth Factor beta | 2 | 2013 | 456 | 0.430 |
Why?
|
| Societies, Medical | 2 | 2015 | 680 | 0.430 |
Why?
|
| Neuromuscular Agents | 1 | 2014 | 67 | 0.430 |
Why?
|
| Double-Blind Method | 4 | 2023 | 1588 | 0.430 |
Why?
|
| Urinary Retention | 2 | 2011 | 17 | 0.420 |
Why?
|
| Histone Deacetylases | 1 | 2013 | 115 | 0.410 |
Why?
|
| Ureterocele | 2 | 2004 | 4 | 0.400 |
Why?
|
| Retrospective Studies | 22 | 2023 | 15981 | 0.400 |
Why?
|
| Deamino Arginine Vasopressin | 3 | 2008 | 7 | 0.390 |
Why?
|
| Child Behavior | 1 | 2013 | 232 | 0.380 |
Why?
|
| Smad1 Protein | 1 | 2011 | 22 | 0.380 |
Why?
|
| Midazolam | 1 | 2011 | 49 | 0.370 |
Why?
|
| Multicystic Dysplastic Kidney | 2 | 2014 | 3 | 0.360 |
Why?
|
| Anti-Anxiety Agents | 1 | 2011 | 72 | 0.360 |
Why?
|
| Patient Reported Outcome Measures | 3 | 2021 | 164 | 0.340 |
Why?
|
| Ultrasonography, Prenatal | 7 | 2008 | 906 | 0.340 |
Why?
|
| Consensus | 4 | 2024 | 612 | 0.330 |
Why?
|
| Female | 34 | 2023 | 65432 | 0.330 |
Why?
|
| Antidiuretic Agents | 1 | 2008 | 1 | 0.320 |
Why?
|
| Cresols | 1 | 2008 | 6 | 0.320 |
Why?
|
| Phenylpropanolamine | 1 | 2008 | 4 | 0.320 |
Why?
|
| Nocturnal Enuresis | 1 | 2008 | 2 | 0.320 |
Why?
|
| Ventilators, Mechanical | 1 | 2008 | 32 | 0.310 |
Why?
|
| Cryptorchidism | 1 | 2008 | 37 | 0.310 |
Why?
|
| Hydronephrosis | 4 | 2014 | 35 | 0.300 |
Why?
|
| Benzhydryl Compounds | 1 | 2008 | 67 | 0.300 |
Why?
|
| Stress, Psychological | 1 | 2013 | 557 | 0.300 |
Why?
|
| Oxygen Consumption | 1 | 2008 | 303 | 0.290 |
Why?
|
| Doxazosin | 2 | 2004 | 27 | 0.290 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2010 | 554 | 0.290 |
Why?
|
| Urethra | 2 | 2022 | 83 | 0.290 |
Why?
|
| Drug Therapy, Combination | 4 | 2021 | 1149 | 0.280 |
Why?
|
| Diverticulum | 1 | 2007 | 28 | 0.280 |
Why?
|
| Anesthesiology | 1 | 2008 | 98 | 0.280 |
Why?
|
| Anxiety | 2 | 2020 | 956 | 0.260 |
Why?
|
| Follow-Up Studies | 7 | 2020 | 5048 | 0.260 |
Why?
|
| Young Adult | 7 | 2020 | 8869 | 0.260 |
Why?
|
| Hemorrhagic Fever, Ebola | 2 | 2016 | 57 | 0.260 |
Why?
|
| Chromosome Aberrations | 1 | 2008 | 614 | 0.250 |
Why?
|
| Mental Disorders | 1 | 2013 | 827 | 0.250 |
Why?
|
| Kidney Transplantation | 2 | 2023 | 629 | 0.250 |
Why?
|
| Adult | 12 | 2023 | 29038 | 0.250 |
Why?
|
| Mice, Inbred C57BL | 5 | 2020 | 4352 | 0.240 |
Why?
|
| Kidney Pelvis | 3 | 2012 | 43 | 0.240 |
Why?
|
| Caregivers | 2 | 2020 | 564 | 0.240 |
Why?
|
| Disease Outbreaks | 2 | 2016 | 320 | 0.230 |
Why?
|
| Growth Substances | 1 | 2004 | 113 | 0.230 |
Why?
|
| Surveys and Questionnaires | 5 | 2024 | 3662 | 0.220 |
Why?
|
| Quality of Life | 4 | 2022 | 1932 | 0.220 |
Why?
|
| Nitric Oxide Synthase | 1 | 2003 | 185 | 0.210 |
Why?
|
| Testicular Hormones | 1 | 2002 | 4 | 0.210 |
Why?
|
| Androstenedione | 1 | 2002 | 10 | 0.210 |
Why?
|
| Delphi Technique | 1 | 2024 | 200 | 0.210 |
Why?
|
| Growth Inhibitors | 1 | 2002 | 37 | 0.210 |
Why?
|
| Urinary Reservoirs, Continent | 2 | 1999 | 21 | 0.210 |
Why?
|
| Age Factors | 6 | 2019 | 2801 | 0.200 |
Why?
|
| Cells, Cultured | 4 | 2013 | 3050 | 0.200 |
Why?
|
| Cohort Studies | 5 | 2020 | 4709 | 0.200 |
Why?
|
| Cloaca | 2 | 2020 | 16 | 0.200 |
Why?
|
| Insurance Coverage | 1 | 2003 | 121 | 0.200 |
Why?
|
| Intestines | 2 | 2012 | 571 | 0.200 |
Why?
|
| Inflammation Mediators | 1 | 2003 | 234 | 0.200 |
Why?
|
| Infant, Newborn | 12 | 2019 | 8089 | 0.200 |
Why?
|
| Pelvic Neoplasms | 1 | 2022 | 21 | 0.200 |
Why?
|
| Lipopolysaccharides | 1 | 2003 | 291 | 0.190 |
Why?
|
| Fascia | 1 | 2001 | 15 | 0.190 |
Why?
|
| Spinal Neoplasms | 1 | 2022 | 59 | 0.190 |
Why?
|
| Obesity | 1 | 2013 | 2229 | 0.190 |
Why?
|
| Sex Factors | 2 | 2018 | 1257 | 0.190 |
Why?
|
| Analgesics | 1 | 2022 | 134 | 0.180 |
Why?
|
| Constriction, Pathologic | 2 | 2023 | 238 | 0.180 |
Why?
|
| Sacrococcygeal Region | 1 | 2020 | 32 | 0.180 |
Why?
|
| Ibuprofen | 1 | 2021 | 42 | 0.180 |
Why?
|
| Hydrocodone | 1 | 2021 | 35 | 0.180 |
Why?
|
| Teratoma | 1 | 2022 | 123 | 0.180 |
Why?
|
| Apoptosis | 3 | 2014 | 1783 | 0.180 |
Why?
|
| Blood Flow Velocity | 1 | 2022 | 448 | 0.180 |
Why?
|
| Puberty | 1 | 2020 | 94 | 0.180 |
Why?
|
| Hydrocephalus | 1 | 2023 | 237 | 0.170 |
Why?
|
| Genetic Heterogeneity | 1 | 2020 | 123 | 0.170 |
Why?
|
| Urologic Surgical Procedures | 5 | 2018 | 58 | 0.170 |
Why?
|
| Cytokines | 2 | 2020 | 1284 | 0.170 |
Why?
|
| Glycoproteins | 1 | 2002 | 369 | 0.170 |
Why?
|
| Hirschsprung Disease | 1 | 2020 | 36 | 0.170 |
Why?
|
| Molecular Weight | 1 | 2020 | 392 | 0.170 |
Why?
|
| Drug Combinations | 1 | 2021 | 271 | 0.170 |
Why?
|
| Fibrosis | 3 | 2016 | 429 | 0.170 |
Why?
|
| Acetaminophen | 1 | 2021 | 91 | 0.170 |
Why?
|
| Anesthetics | 1 | 2020 | 81 | 0.170 |
Why?
|
| Bladder Exstrophy | 1 | 1999 | 10 | 0.170 |
Why?
|
| Animals | 12 | 2020 | 33741 | 0.160 |
Why?
|
| Ebolavirus | 2 | 2016 | 45 | 0.160 |
Why?
|
| Urologists | 1 | 2019 | 10 | 0.160 |
Why?
|
| Urogenital System | 1 | 2019 | 34 | 0.160 |
Why?
|
| Kidney Tubules | 2 | 2016 | 82 | 0.160 |
Why?
|
| Cystadenoma, Papillary | 1 | 1998 | 3 | 0.160 |
Why?
|
| Patients | 1 | 2020 | 121 | 0.160 |
Why?
|
| Mice | 9 | 2016 | 17498 | 0.160 |
Why?
|
| Child Health | 1 | 2019 | 53 | 0.160 |
Why?
|
| Pediatricians | 1 | 2019 | 65 | 0.150 |
Why?
|
| Pilot Projects | 2 | 2022 | 1387 | 0.150 |
Why?
|
| Attitude to Health | 1 | 2020 | 260 | 0.150 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2019 | 66 | 0.150 |
Why?
|
| Physical Examination | 1 | 2019 | 164 | 0.150 |
Why?
|
| Enuresis | 3 | 2008 | 6 | 0.150 |
Why?
|
| Gonadal Dysgenesis, 46,XY | 1 | 2017 | 17 | 0.150 |
Why?
|
| Testosterone | 1 | 2002 | 462 | 0.150 |
Why?
|
| Anesthesia | 1 | 2020 | 212 | 0.150 |
Why?
|
| Testicular Neoplasms | 1 | 1998 | 133 | 0.150 |
Why?
|
| Adrenal Hyperplasia, Congenital | 1 | 2017 | 34 | 0.140 |
Why?
|
| Enema | 1 | 2017 | 37 | 0.140 |
Why?
|
| Risk Assessment | 5 | 2019 | 3332 | 0.140 |
Why?
|
| Organ Size | 1 | 2018 | 412 | 0.140 |
Why?
|
| Preoperative Period | 1 | 2017 | 82 | 0.140 |
Why?
|
| Nephrectomy | 1 | 2018 | 172 | 0.140 |
Why?
|
| Patient Satisfaction | 1 | 2021 | 477 | 0.140 |
Why?
|
| Stomach | 1 | 1999 | 271 | 0.140 |
Why?
|
| NFATC Transcription Factors | 2 | 2014 | 42 | 0.140 |
Why?
|
| Ambulatory Care Facilities | 1 | 2019 | 229 | 0.140 |
Why?
|
| Angiopoietin-1 | 1 | 2016 | 7 | 0.140 |
Why?
|
| Gene Expression | 2 | 2016 | 1569 | 0.130 |
Why?
|
| Ureteral Neoplasms | 1 | 2016 | 24 | 0.130 |
Why?
|
| Symptom Assessment | 1 | 2016 | 98 | 0.130 |
Why?
|
| Gastric Mucosa | 1 | 1999 | 483 | 0.130 |
Why?
|
| Epidemics | 1 | 2016 | 53 | 0.130 |
Why?
|
| Respiratory Tract Diseases | 1 | 2016 | 76 | 0.130 |
Why?
|
| Fibroblasts | 1 | 2020 | 878 | 0.130 |
Why?
|
| Clinical Decision-Making | 1 | 2017 | 266 | 0.130 |
Why?
|
| Disease Models, Animal | 3 | 2016 | 4268 | 0.130 |
Why?
|
| Spinal Cord | 1 | 2017 | 293 | 0.130 |
Why?
|
| Ileum | 1 | 2016 | 132 | 0.130 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2018 | 576 | 0.130 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2015 | 33 | 0.120 |
Why?
|
| Self Report | 1 | 2018 | 514 | 0.120 |
Why?
|
| Caspase 3 | 1 | 2015 | 131 | 0.120 |
Why?
|
| Databases, Factual | 3 | 2019 | 1169 | 0.120 |
Why?
|
| Fetal Diseases | 1 | 1998 | 440 | 0.120 |
Why?
|
| Adenoma | 1 | 2016 | 133 | 0.120 |
Why?
|
| RNA, Messenger | 3 | 2013 | 2820 | 0.120 |
Why?
|
| Prevalence | 1 | 2021 | 2405 | 0.120 |
Why?
|
| Intestinal Mucosa | 1 | 1999 | 774 | 0.120 |
Why?
|
| Longitudinal Studies | 1 | 2018 | 1315 | 0.120 |
Why?
|
| Organogenesis | 1 | 2014 | 77 | 0.110 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2014 | 62 | 0.110 |
Why?
|
| Attitude of Health Personnel | 1 | 2019 | 640 | 0.110 |
Why?
|
| ADAM Proteins | 1 | 2014 | 79 | 0.110 |
Why?
|
| Neural Tube Defects | 1 | 2017 | 351 | 0.110 |
Why?
|
| Lymphangitis | 1 | 2013 | 5 | 0.110 |
Why?
|
| Transcription, Genetic | 3 | 2014 | 1695 | 0.110 |
Why?
|
| Urography | 2 | 2011 | 31 | 0.110 |
Why?
|
| Missouri | 1 | 2013 | 36 | 0.110 |
Why?
|
| Reference Standards | 1 | 2014 | 241 | 0.110 |
Why?
|
| Antigens, CD | 1 | 2015 | 420 | 0.110 |
Why?
|
| Granuloma | 1 | 2013 | 67 | 0.100 |
Why?
|
| Research Design | 1 | 2017 | 688 | 0.100 |
Why?
|
| Disease Progression | 2 | 2017 | 2027 | 0.100 |
Why?
|
| Referral and Consultation | 1 | 2016 | 527 | 0.100 |
Why?
|
| Diagnostic Techniques, Urological | 1 | 2012 | 6 | 0.100 |
Why?
|
| Gastrointestinal Diseases | 1 | 2016 | 335 | 0.100 |
Why?
|
| Up-Regulation | 2 | 2014 | 868 | 0.100 |
Why?
|
| Robotic Surgical Procedures | 1 | 2016 | 194 | 0.100 |
Why?
|
| Fecal Incontinence | 1 | 2012 | 69 | 0.100 |
Why?
|
| Pediatrics | 2 | 2024 | 1139 | 0.090 |
Why?
|
| Injections, Intralesional | 1 | 2011 | 48 | 0.090 |
Why?
|
| Cystoscopy | 1 | 2011 | 44 | 0.090 |
Why?
|
| Phenotype | 1 | 2020 | 4225 | 0.090 |
Why?
|
| Physical Therapy Modalities | 1 | 2011 | 50 | 0.090 |
Why?
|
| Signal Transduction | 4 | 2016 | 4508 | 0.090 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2010 | 58 | 0.090 |
Why?
|
| Laparoscopy | 1 | 2016 | 501 | 0.090 |
Why?
|
| Crohn Disease | 1 | 2013 | 283 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2018 | 3518 | 0.080 |
Why?
|
| Biomechanical Phenomena | 1 | 2010 | 246 | 0.080 |
Why?
|
| Treatment Failure | 2 | 2008 | 338 | 0.080 |
Why?
|
| Tolterodine Tartrate | 1 | 2008 | 3 | 0.080 |
Why?
|
| Mechanotransduction, Cellular | 1 | 2009 | 60 | 0.080 |
Why?
|
| Administration, Oral | 1 | 2011 | 671 | 0.080 |
Why?
|
| Capsules | 1 | 2008 | 21 | 0.080 |
Why?
|
| Sexual Development | 2 | 2019 | 23 | 0.080 |
Why?
|
| Behavior Therapy | 1 | 2011 | 256 | 0.080 |
Why?
|
| Cross-Sectional Studies | 3 | 2022 | 3377 | 0.070 |
Why?
|
| Comorbidity | 1 | 2013 | 1498 | 0.070 |
Why?
|
| Renal Agents | 2 | 1998 | 5 | 0.070 |
Why?
|
| Brain | 1 | 2019 | 2947 | 0.070 |
Why?
|
| Psychometrics | 2 | 2022 | 667 | 0.070 |
Why?
|
| Combined Modality Therapy | 1 | 2011 | 1240 | 0.070 |
Why?
|
| Body Mass Index | 1 | 2013 | 1543 | 0.070 |
Why?
|
| Sierra Leone | 2 | 2016 | 30 | 0.070 |
Why?
|
| Membrane Proteins | 1 | 2014 | 1528 | 0.070 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2015 | 715 | 0.070 |
Why?
|
| Cell Division | 2 | 2004 | 779 | 0.060 |
Why?
|
| Pregnancy | 4 | 2008 | 7124 | 0.060 |
Why?
|
| HIV Infections | 1 | 2016 | 1868 | 0.060 |
Why?
|
| Anemia, Sickle Cell | 1 | 2008 | 334 | 0.060 |
Why?
|
| Hospitals, Maternity | 1 | 2003 | 8 | 0.060 |
Why?
|
| Risk Factors | 2 | 2017 | 10001 | 0.060 |
Why?
|
| Midwestern United States | 1 | 2003 | 17 | 0.060 |
Why?
|
| Cell Proliferation | 3 | 2020 | 2308 | 0.060 |
Why?
|
| Middle Aged | 4 | 2017 | 25980 | 0.060 |
Why?
|
| Utilization Review | 1 | 2003 | 38 | 0.060 |
Why?
|
| Guanidines | 1 | 2003 | 25 | 0.060 |
Why?
|
| Collagen Type III | 1 | 2003 | 21 | 0.060 |
Why?
|
| Health Care Sector | 1 | 2003 | 19 | 0.060 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2003 | 94 | 0.050 |
Why?
|
| Hospitals, Community | 1 | 2003 | 55 | 0.050 |
Why?
|
| Medically Uninsured | 1 | 2003 | 73 | 0.050 |
Why?
|
| Interleukin-1 | 1 | 2003 | 141 | 0.050 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2019 | 711 | 0.050 |
Why?
|
| Steroid 17-alpha-Hydroxylase | 1 | 2002 | 7 | 0.050 |
Why?
|
| Severity of Illness Index | 1 | 2011 | 2838 | 0.050 |
Why?
|
| Ventriculoperitoneal Shunt | 1 | 2023 | 49 | 0.050 |
Why?
|
| Anti-Mullerian Hormone | 1 | 2002 | 37 | 0.050 |
Why?
|
| Urinary Incontinence, Stress | 1 | 2001 | 30 | 0.050 |
Why?
|
| Reference Values | 1 | 2002 | 696 | 0.050 |
Why?
|
| Medicaid | 1 | 2003 | 244 | 0.050 |
Why?
|
| Interferon-gamma | 1 | 2003 | 511 | 0.050 |
Why?
|
| Training Support | 1 | 2020 | 17 | 0.050 |
Why?
|
| Nurse Anesthetists | 1 | 2020 | 13 | 0.050 |
Why?
|
| Anesthesia, Caudal | 1 | 2020 | 15 | 0.050 |
Why?
|
| Rectum | 1 | 2001 | 98 | 0.040 |
Why?
|
| Anesthesiologists | 1 | 2020 | 36 | 0.040 |
Why?
|
| Cause of Death | 1 | 2023 | 459 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2003 | 670 | 0.040 |
Why?
|
| Nitric Oxide | 1 | 2003 | 432 | 0.040 |
Why?
|
| Pelvic Floor | 1 | 2020 | 34 | 0.040 |
Why?
|
| Pulmonary Alveoli | 1 | 2020 | 132 | 0.040 |
Why?
|
| Uncertainty | 1 | 2020 | 99 | 0.040 |
Why?
|
| Operative Time | 1 | 2020 | 160 | 0.040 |
Why?
|
| Reproducibility of Results | 2 | 2022 | 2851 | 0.040 |
Why?
|
| Mice, Transgenic | 2 | 2016 | 2391 | 0.040 |
Why?
|
| Recurrence | 1 | 2003 | 1420 | 0.040 |
Why?
|
| Ploidies | 1 | 1999 | 37 | 0.040 |
Why?
|
| Genitalia, Male | 1 | 2019 | 37 | 0.040 |
Why?
|
| Patient-Centered Care | 1 | 2022 | 225 | 0.040 |
Why?
|
| Program Development | 1 | 2020 | 190 | 0.040 |
Why?
|
| Extracellular Matrix | 1 | 2020 | 231 | 0.040 |
Why?
|
| Health Status | 1 | 2021 | 374 | 0.040 |
Why?
|
| Dextrans | 1 | 2018 | 46 | 0.040 |
Why?
|
| Hormones | 1 | 2019 | 190 | 0.040 |
Why?
|
| Documentation | 1 | 2019 | 115 | 0.040 |
Why?
|
| Prostate-Specific Antigen | 1 | 1999 | 247 | 0.040 |
Why?
|
| Tertiary Care Centers | 1 | 2019 | 236 | 0.040 |
Why?
|
| Statistics, Nonparametric | 1 | 2019 | 426 | 0.040 |
Why?
|
| Hyaluronic Acid | 1 | 2018 | 96 | 0.040 |
Why?
|
| Qualitative Research | 1 | 2021 | 522 | 0.040 |
Why?
|
| Dilatation, Pathologic | 2 | 2008 | 93 | 0.040 |
Why?
|
| Reoperation | 1 | 2020 | 819 | 0.040 |
Why?
|
| Prostheses and Implants | 1 | 2018 | 151 | 0.040 |
Why?
|
| Infectious Disease Incubation Period | 1 | 2016 | 7 | 0.030 |
Why?
|
| Urine | 1 | 1997 | 88 | 0.030 |
Why?
|
| Surgeons | 1 | 2020 | 247 | 0.030 |
Why?
|
| Microcirculation | 1 | 2016 | 93 | 0.030 |
Why?
|
| Collagen Type I | 1 | 2016 | 110 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2017 | 298 | 0.030 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2016 | 127 | 0.030 |
Why?
|
| Malaria | 1 | 2016 | 82 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2016 | 6372 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2016 | 272 | 0.030 |
Why?
|
| Neovascularization, Pathologic | 1 | 2016 | 240 | 0.030 |
Why?
|
| Mortality | 1 | 2016 | 230 | 0.030 |
Why?
|
| Fatigue | 1 | 2016 | 217 | 0.030 |
Why?
|
| Aquaporin 2 | 1 | 2014 | 4 | 0.030 |
Why?
|
| Kidney Tubules, Collecting | 1 | 2014 | 7 | 0.030 |
Why?
|
| ADAM10 Protein | 1 | 2014 | 10 | 0.030 |
Why?
|
| Viral Load | 1 | 2016 | 382 | 0.030 |
Why?
|
| Patient Safety | 1 | 2019 | 390 | 0.030 |
Why?
|
| Polyuria | 1 | 2014 | 12 | 0.030 |
Why?
|
| Predictive Value of Tests | 3 | 2012 | 2108 | 0.030 |
Why?
|
| Diarrhea | 1 | 2016 | 315 | 0.030 |
Why?
|
| Actins | 1 | 2016 | 341 | 0.030 |
Why?
|
| Hospitals, Pediatric | 1 | 2019 | 780 | 0.030 |
Why?
|
| Calcineurin | 1 | 2014 | 100 | 0.030 |
Why?
|
| Health Personnel | 1 | 2019 | 500 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2016 | 515 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2016 | 383 | 0.030 |
Why?
|
| United States | 2 | 2019 | 10618 | 0.030 |
Why?
|
| Fever | 1 | 2016 | 296 | 0.030 |
Why?
|
| Lymphedema | 1 | 2013 | 19 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2016 | 1294 | 0.030 |
Why?
|
| Cadherins | 1 | 2014 | 164 | 0.030 |
Why?
|
| Inflammation | 1 | 2020 | 1404 | 0.030 |
Why?
|
| Wnt Signaling Pathway | 1 | 2014 | 195 | 0.030 |
Why?
|
| Ligands | 1 | 2014 | 533 | 0.030 |
Why?
|
| Ureteroscopy | 1 | 2012 | 17 | 0.030 |
Why?
|
| Prednisone | 1 | 2013 | 273 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 2013 | 230 | 0.030 |
Why?
|
| Metronidazole | 1 | 2013 | 155 | 0.030 |
Why?
|
| Receptors, Notch | 1 | 2014 | 202 | 0.030 |
Why?
|
| Depression | 1 | 2020 | 1225 | 0.020 |
Why?
|
| Forkhead Transcription Factors | 1 | 2014 | 370 | 0.020 |
Why?
|
| Wolffian Ducts | 1 | 2011 | 10 | 0.020 |
Why?
|
| Benchmarking | 1 | 2012 | 132 | 0.020 |
Why?
|
| Aged | 3 | 2016 | 19072 | 0.020 |
Why?
|
| Cell Death | 1 | 2011 | 242 | 0.020 |
Why?
|
| Internship and Residency | 1 | 2020 | 1158 | 0.020 |
Why?
|
| Prostatic Neoplasms | 1 | 1999 | 1515 | 0.020 |
Why?
|
| S-Phase Kinase-Associated Proteins | 1 | 2009 | 17 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2014 | 901 | 0.020 |
Why?
|
| Consensus Sequence | 1 | 2009 | 58 | 0.020 |
Why?
|
| Sensitivity and Specificity | 2 | 2006 | 2024 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2013 | 1684 | 0.020 |
Why?
|
| Solubility | 1 | 2009 | 131 | 0.020 |
Why?
|
| Tissue Culture Techniques | 1 | 2009 | 70 | 0.020 |
Why?
|
| Stem Cells | 1 | 2014 | 701 | 0.020 |
Why?
|
| Stress, Mechanical | 1 | 2009 | 171 | 0.020 |
Why?
|
| Kidney Calices | 1 | 2008 | 4 | 0.020 |
Why?
|
| Cell Separation | 1 | 2009 | 233 | 0.020 |
Why?
|
| Nocturia | 1 | 2008 | 1 | 0.020 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2009 | 160 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2012 | 619 | 0.020 |
Why?
|
| Protein Transport | 1 | 2009 | 370 | 0.020 |
Why?
|
| Hospitalization | 1 | 2016 | 1733 | 0.020 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2009 | 281 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2016 | 2533 | 0.020 |
Why?
|
| Time Factors | 1 | 2017 | 6201 | 0.020 |
Why?
|
| Osmolar Concentration | 2 | 1998 | 172 | 0.020 |
Why?
|
| Administration, Intranasal | 2 | 1998 | 130 | 0.020 |
Why?
|
| Biomarkers | 1 | 2016 | 2943 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 2009 | 674 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2003 | 1684 | 0.020 |
Why?
|
| ROC Curve | 1 | 2008 | 557 | 0.020 |
Why?
|
| Binding Sites | 1 | 2009 | 1292 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2009 | 1338 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2009 | 1611 | 0.020 |
Why?
|
| Pain | 1 | 2008 | 470 | 0.010 |
Why?
|
| Base Sequence | 1 | 2009 | 3093 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2009 | 3871 | 0.010 |
Why?
|
| Prognosis | 1 | 2012 | 4509 | 0.010 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2003 | 117 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2003 | 730 | 0.010 |
Why?
|
| Urologic Surgical Procedures, Male | 1 | 2001 | 38 | 0.010 |
Why?
|
| Mutation | 1 | 2014 | 5778 | 0.010 |
Why?
|
| Endoscopy | 1 | 2001 | 283 | 0.010 |
Why?
|
| Prostatic Hyperplasia | 1 | 1999 | 106 | 0.010 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 1999 | 93 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2002 | 1872 | 0.010 |
Why?
|
| Urinalysis | 1 | 1997 | 62 | 0.010 |
Why?
|
| Probability | 1 | 1997 | 322 | 0.010 |
Why?
|
| Circadian Rhythm | 1 | 1998 | 269 | 0.010 |
Why?
|
| Logistic Models | 1 | 1997 | 1799 | 0.010 |
Why?
|